Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;18(6):303-11.

Racial disparities in lipid control in patients with diabetes

Darcy Saffar  1 , Keoki Williams, Jennifer Elston Lafata, George Divine, Manel Pladevall
Affiliations

Racial disparities in lipid control in patients with diabetes

Darcy Saffar et al. Am J Manag Care. 2012 Jun.

Abstract

Objectives: To describe lipid management over time in a cohort of insured patients with diabetes and evaluate differences between African American and white patients.

Study design: Automated claims data were used to identify a cohort of 11,411 patients with diabetes in 1997 to 1998. Patients were followed through 2007.

Methods: Rates of hypercholesterolemia testing, treatment, and goal attainment were measured annually. Treatment was determined by a claim for lipid-lowering agents, and goal attainment was defined as a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL.

Results: During the study period, LDL-C testing increased from 48% to 70% among African American patients and from 61% to 77% among white patients. Treatment with lipid-lowering drugs increased from 23% to 56% among African American patients and 33% to 61% among white patients. The proportion at goal increased from 35% to 76% and from 24% to 59% among white and African American patients, respectively. African American patients were less likely to be tested for LDL-C (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.73-0.86), treated with lipidlowering agents (OR 0.72; 95% CI 0.65-0.80), have their medication dosage altered (OR 0.65; 95% CI 0.59-0.73), or attain LDL-C goal (OR 0.59; 95% CI 0.56-0.63) compared with white patients.

Conclusions: Although rates of LDL-C testing, treatment, and goal attainment improved over time, racial disparities in dyslipidemia management continued to exist. Further studies to determine the causes of differences in management by race are warranted.

PubMed Disclaimer

References

    1. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, et al. How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diab Med. 2008;25(12):1433–1439. - PubMed
    1. Gerstein HC, Swedberg M, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008;168(15):1699–1704. - PubMed
    1. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the US for the diagnosis and treatment of dyslipidemia. Circulation. 2007;115(11):1363–1370. - PubMed
    1. Wierzbicki AS. Interpreting clinical trials of diabetic dyslipdaemia: new insights. Diabetes Obes Metab. 2009;11(3):261–270. - PubMed
    1. Clark LT, Maki KC, Galant R, Maran DJ, Pearson TA, Davidson MH. Ethnic differences in achievement of cholesterol treatment goals. J Gen Intern Med. 2006;21(4):320–326. - PMC - PubMed

Publication types

MeSH terms